<DOC>
	<DOCNO>NCT01150669</DOCNO>
	<brief_summary>This research study study lestaurtinib chemotherapy sample young patient leukemia . Studying effect lestaurtinib without chemotherapy cell sample patient cancer laboratory may help doctor learn effect treatment cancer cell . It may also help doctor identify biomarkers related cancer .</brief_summary>
	<brief_title>Lestaurtinib With Without Chemotherapy Agents Samples From Young Patients With Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine potential lestaurtinib without chemotherapy agent treat sample infant leukemia . II . Determine whether FLT3 protein expression level and/or activation sensitivity lestaurtinib differ subgroup infant leukemia . III . Determine whether lestaurtinib activates STAT5 , AKT , RAS-MAPK pathway . IV . Determine whether lestaurtinib synergize chemotherapy agent kill infant leukemia cell . OUTLINE : This multicenter study . Cryopreserved specimens study vitro lestaurtinib without chemotherapy agent . Samples analyze FLT3 protein expression and/or activation ; sensitivity lestaurtinib without chemotherapy agent ; activation STAT , AKT , RAS-MAPK pathways western blot . The effective treatment study validate vivo NOD/SCID xenograft model .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<criteria>Cryopreserved sample infant leukemia available</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>